Advertisement

Topics

rEVO Biologics Company Profile

00:07 EDT 18th October 2017 | BioPortfolio

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recombinant therapies. Through its proprietary rPRO Technology platform -- a scalable, transgenic, and cost-effective method of protein production-- rEVO Biologics is bringing safe and reliable therapeutic proteins to address critical medical needs. The company’s lead product, ATryn® Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009. The company has a number of products in its pipeline and in clinical trials in the areas of hematology, oncology, genetic disorders and autoimmune disease, and is actively seeking additional indications for its lead product.


News Articles [408 Associated News Articles listed on BioPortfolio]

rEVO Biologics Inc Strategic SWOT Analysis Review [Report Updated: 08082017] Prices from USD $125

rEVO Biologics Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SW...

DSM Biologics: Karen King on New Technology and Reducing the Cost of Medicines

In this episode of PharmaTelevision News Review, Fintan Walton talks with Karen King, President and Business Unit Director of DSM Biologics. Filmed at BioChicago 2010 in Chicago, USA, they discuss: ...

Publication of the Securities Note Having Obtained Visa No. 17-297 of the AMF in Connection with the Capital Increase of GenSight Biologics

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN. Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), ("GenSight Biologics...

Heat Biologics, Inc.: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma

Samsung Bioepis, a division of Samsung Biologics, announced a joint venture with Japan's Takeda Pharma to develop novel biologic drugs. The JV's first project will be TAK-671, a candidate aimed at sev...

Heat Biologics, Inc.: Heat Biologics Appoints Damien Hallet as Vice President of CMC Development

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Samsung Bioepis and Takeda enter biologics co-development deal

Samsung Bioepis Co. Ltd., a joint venture formed by Samsung BioLogics and Biogen Inc., and Takeda Pharmaceutical Co. Ltd. entered an agreement to co-fund and co-develop biologics for diseases of unmet...

Samsung BioLogics' New Plant Approved by FDA

Samsung BioLogics, a Korean biologics CMO, received US FDA approval to produce an antibody drug substance at its second plant. The second facility, currently Samsung's largest, was completed in March ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [104 Associated PubMed Articles listed on BioPortfolio]

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our syste...

Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study.

Biologics are usually licensed according to the "one dose fits all" principle. It is therefore suspected that a significant number of psoriasis patients are overtreated. However, evidence for successf...

Biosimilars: biologics that meet patients' needs and healthcare economics.

Biologics have revolutionized medical care, yet uniform access to these effective medicines remains difficult due to the increasing costs of healthcare. As patent exclusivity on the early biologics wa...

The expanding field of biologics in the management of chronic urticaria.

Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternati...

Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.

There are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood.

Clinical Trials [62 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [237 Associated Companies listed on BioPortfolio]

rEVO Biologics

rEVO Biologics is a rare disease company focused on developing and delivering first and next-generation therapeutics that are more cost effective to produce than traditional recom...

rEVO Biologics Inc.

rEVO Biologics Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address ...

rEVO Biologics, Inc.

rEVO Biologics, Inc. (www.revobiologics.com) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address ...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

More Information about "rEVO Biologics" on BioPortfolio

We have published hundreds of rEVO Biologics news stories on BioPortfolio along with dozens of rEVO Biologics Clinical Trials and PubMed Articles about rEVO Biologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of rEVO Biologics Companies in our database. You can also find out about relevant rEVO Biologics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record